SCHEMBL279582

SCHEMBL279582

Cc1ccc(C(=O)NN)s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.62
POLB P06746 2/20 0.62
TDP1 Q9NUW8 1/20 0.62
TAS1R3 Q7RTX0 1/20 0.62
TAS1R1 Q7RTX1 1/20 0.62
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 2/20 0.59
MAPT P10636 2/20 0.59
NPC1 O15118 10/20 0.57
RAB9A P51151 9/20 0.57
MEN1 O00255 5/20 0.57
DAO P14920 1/20 0.57
SMN1; SMN2 Q16637 5/20 0.51
USP2 O75604 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 3/20 0.47
HPGD P15428 2/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276955 0.84 ALDH1A1 (0.58) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL12124464 0.83 DAO (0.61) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL7967944 0.81 KMT2A (0.59) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL12124251 0.80 TAS1R3 (0.63) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL12124277 0.80 KMT2A (0.69) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL12124273 0.80 KMT2A (0.54) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL15296767 0.80 POLB (0.73) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL16313561 0.80 POLB (0.63) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL19316038 0.79 HDAC6 (0.56) KMT2APOLBTDP1TAS1R3TAS1R1
SCHEMBL1587423 0.79 ALDH1A1 (0.54) KMT2APOLBTDP1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022035763-A1 BORON CONTAINING COMPOUNDS AND THEIR USES 5METIS, INC. (US) 2022-02-17 WO disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
WO-2020264581-A1 BORON CONTAINING COMPOUNDS AND THEIR USES Boragen, Inc. (US) 2020-12-30 WO disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3309161-B1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR JANSSEN PHARMACEUTICA NV (BE) 2019-12-18 EP disclosed
US-10367148-B2 Light-emitting device, electronic apparatus, and inspection method SEIKO EPSON CORPORATION (JP) 2019-07-30 US disclosed
US-10367148-B2 Light-emitting device, electronic apparatus, and inspection method SEIKO EPSON CORPORATION (JP) 2019-07-30 US disclosed
CN-106463633-B Light emitting device, electronic equipment and inspection method 精工爱普生株式会社 2019-03-15 CN disclosed
US-10053462-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2018-08-21 US disclosed
US-10053463-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2018-08-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
EP-1478364-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2004-11-24 EP disclosed
WO-2003039549-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2003-05-15 WO disclosed
EP-0915875-B1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2003-04-09 EP disclosed
CN-1379777-A Amino-triazolopyridine derivatives HOFFMANN LA ROCHE (CH) 2002-11-13 CN disclosed
EP-1214322-A2 AMINO-TRIAZOLOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-19 EP disclosed
US-6355653-B1 DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS HOFFMANN-LA ROCHE INC. 2002-03-12 US disclosed
US-6255305-B1 PSYCHOLOGICAL DISORDERS MERCK SHARP & DOHME LIMITED (GB) 2001-07-03 US disclosed
WO-2001017999-A2 AMINO-TRIAZOLOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053462-B2 P2X7 modulators P2RX1, P2RX5, P2RX7 KMT2A 4025/4885POLB 4258/4885TDP1 2301/4885
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R KMT2A 3480/4885POLB 4304/4885TDP1 3780/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885POLB 4352/4885TDP1 2969/4885
US-10367148-B2 Light-emitting device, electronic apparatus, and inspection method CRY1, INF2, CRY2 KMT2A 1246/4885POLB 3051/4885TDP1 2845/4885
US-10053463-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators HTR5A, P2RX5, P2RX3 KMT2A 3955/4885POLB 2399/4885TDP1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.